COG.GB Cambridge Cognition Holdings PLC

TIDMCOG

RNS Number : 8846V

Cambridge Cognition Holdings PLC

12 April 2023

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

Cambridge Cognition awarded two contracts worth GBP2.1 million for rare disease trials

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won two sizeable contracts, together worth over GBP2.1 million, to provide the Company's CANTAB(R) cognitive assessments and electronic Clinical Outcome Assessments ("eCOA") for two pivotal trials involving patients with a rare disease. The contracts have been awarded by a new customer for the Company with revenues expected to be recognised over the next five years.

A rare disease is a condition that affects fewer than one in 2,000 people within the general population. While each individual disease may only affect a small amount of people, collectively, rare diseases affect about 6-8% of the population. Rare diseases are often associated with neurodevelopmental issues and cognitive dysfunction. Cambridge Cognition are widely recognised for proprietary cognitive assessments (CANTAB(R)) that are sensitive to the specific neural pathways impacted by disorders and improved by therapeutics. The Company therefore provides a valuable solution for pharmaceutical companies developing new drugs for a rare disease that may help improve the patient's cognitive function.

Every clinical trial includes questionnaires and is seeking a seamless experience for both patient and site. Recognising this need, Cambridge Cognition offers both eCOA and cognitive assessments in a single, easy-to-use platform. This unique product offering combined with the Company's extensive multi-site, multi-country project management experience secured Cambridge Cognition these two pivotal trials with a new customer.

Participation in these trials will enable Cambridge Cognition to offer more insights into the use of digital cognitive assessments and eCOA solutions as part of rare disease trials, including how effective these methods are for use in long-term studies.

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said: "Over the past five years Cambridge Cognition has developed a unique offering for clinical trials of leading cognitive assessments (CANTAB(R)) and electronic questionnaires (eCOA) in a single, easy-to-use platform. This, combined with our reputation for outstanding customer service and cutting-edge science, has enabled us to secure two large contracts with a new customer. These contracts will strengthen our presence in the rare disease field and showcase how our cognitive assessments can be used effectively in the development of symptom modifying treatments."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.

Enquiries

 
Cambridge Cognition Holdings Plc                     Tel: 012 2381 0700 
 Matthew Stork, Chief Executive Officer                press@camcog.com 
 Stephen Symonds, Chief Financial Officer 
Panmure Gordon (UK) Limited (NOMAD and Joint         Tel: 020 7886 2500 
 Broker)                                            (Corporate Finance) 
 Freddy Crossley / Emma Earl                        (Corporate Broking) 
 Rupert Dearden 
Dowgate Capital Limited (Joint Broker)               Tel: 020 3903 7715 
 David Poutney / James Serjeant 
IFC Advisory Ltd (Financial PR and IR)               Tel: 020 3934 6630 
 Tim Metcalfe / Graham Herring / Zach Cohen    cog@investor-focus.co.uk 
 

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTDFLFFXZLLBBD

(END) Dow Jones Newswires

April 12, 2023 02:00 ET (06:00 GMT)

Cambridge Cognition (AQSE:COG.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Cambridge Cognition (AQSE:COG.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024